$AMGN: Amgen Reports Imdelltra-Imfinzi Combo Cut Death Risk by 58% in First-L

$AMGN

$AMGN � Amgen Reports Imdelltra-Imfinzi Combo Cut Death Risk by 58% in First-Line SCLC

2026-10-24 14:38:23 UTC � TELEGRAM � All $AMGN

?? Positive AI Sentiment (+6.8 / 10)

• Nearly 80% 1-year survival rate vs 53% for monotherapy in extensive-stage small cell lung cancer. • Progression-free survival (PFS) more than tripled under combination regimen. • Represents significant clinical outperformance and commercial expansion potential for Imdelltra.